HONG KONG, June 16, 2026 /PRNewswire/ — MetaLight Inc. (“MetaLight” or the “Company”; Stock Code: 02605.HK), a public transit information service provider powered by time series data analytics and AI technology, today announced that a peer-reviewed research paper co-authored with Peking University and other institutions has been accepted to the Applied Data Science (ADS) Track of KDD 2026. Titled “A Data-driven Route Segmentation Framework for Time-of-Arrival Estimation Service,” the paper’s authors are affiliated with Peking University, MetaLight HK Limited (a member of the Group) and other institutions, and its first author is from Peking University; the Company’s Chairman and CEO, Dr. Sun Xi, is a co-author. It addresses route segmentation — a previously underexplored step in bus arrival-time estimation (ETA); the Company’s team, drawing on its Chelaile platform, provided the real-world data and the online deployment environment for the work.

KDD (the ACM SIGKDD Conference on Knowledge Discovery and Data Mining), organized by ACM SIGKDD, is rated a Class A recommended conference by the China Computer Federation (CCF) and will be held in Jeju, South Korea, from August 9 to 13, 2026. Accepted in the track’s second review cycle (Cycle Two), the paper will be included in the proceedings and presented at the conference by its authors.

In bus ETA, a route is typically divided into segments using predefined markers such as intersections, with traffic data aggregated accordingly. Coarse segmentation can blur fine-grained differences in traffic conditions along the same route and constrain prediction accuracy. The research instead draws on large-scale, fine-grained vehicle trajectory data to segment routes so that each segment corresponds to a relatively stable traffic regime, characterizing real traffic variation along a route more precisely.

In offline evaluations covering over a thousand routes and more than a million trajectories, the method outperformed commonly used route-segmentation strategies. In a one-week online evaluation on the Chelaile service across two cities, it reduced storage usage by approximately 90% and CPU usage by approximately 25% at comparable prediction accuracy.

Prior ETA research has focused largely on the prediction model itself, with less attention to how a route is segmented and how its data is organized; this work indicates that this step is just as important to prediction accuracy and operational efficiency. In the Company’s bus ETA service, the approach has materially lowered storage and compute requirements at comparable accuracy, making the large-scale online service lighter to run.

Beyond the work accepted to KDD 2026, MetaLight has in recent years also co-authored papers in temporal point processes (with Renmin University of China, Shanghai Jiao Tong University and Fudan University, accepted to AAAI 2026) and model merging (with Shanghai Jiao Tong University and the Shanghai Artificial Intelligence Laboratory, accepted to IJCNN 2025).

A representative of MetaLight said, “This work benefited from the collaboration of our team with Peking University and other partners. We care more about whether technology solves concrete problems in real-world settings, and we also hope to foster an internal culture of active learning and continuous evolution; we will keep building our foundational technology steadily, through long-term investment and collaboration.”

About MetaLight

MetaLight Inc. (Stock Code: 02605.HK) is a public transit information service provider powered by time series data analytics and AI technology. With a focus on time series data foundation models, the Company has built a technology stack with its core comprising an AI Model Building Platform and AI model libraries for three industry verticals: public bus, renewable energy and industrial internet, integrating capabilities in data access, pre-processing, labeling, AI model training and foundation model adaptation. Based on this technology stack, the Company operates the Chelaile real-time public transit information platform, providing commuters with services including real-time bus arrival predictions, vehicle location tracking and travel route planning, while also offering public transit analytics platforms and data technology services to transport operators. According to CIC data as of December 31, 2024, Chelaile is the largest real-time public transit information platform in China by city coverage. As of December 31, 2025, it covered 488 cities and towns nationwide with approximately 334 million cumulative users, committed to making public transit more convenient and efficient. For more information, please visit www.metalight.ai.

Forward-Looking Statements

In addition to statements of historical fact, this press release contains forward-looking statements relating to the Company’s business outlook, estimates of financial performance, forecast business plans, development strategies and projections of anticipated trends in our industry. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “might,” “can,” “could,” “will,” “would,” “expect,” “believe,” “continue,” “estimate,” “anticipate,” “forecast,” “intend,” “plan,” “seek” or “timetable.” Such forward-looking statements are based on the information available to the Company and the outlook as at the time of publication of this press release. Such forward-looking statements are based on certain projections, assumptions and premises, some of which involve subjective factors or factors beyond our control. Such forward-looking statements may prove to be inaccurate and may not materialize in the future. Such forward-looking statements involve a number of risks and uncertainties. In view of the risks and uncertainties, forward-looking statements contained in this press release should not be construed as representations by the Board or the Company that such plans and objectives will be achieved, and investors should not place undue reliance on such statements. Except as required by law, neither the Company, its Board, employees nor agents assume any obligation to publicly release any revisions, corrections or updates to the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release or unanticipated events, nor do they assume any liability for any losses arising from the failure to realize or inaccuracy of any forward-looking statements.

Investor and Media Inquiries

MetaLight Inc.
Investor Relations
Email: ir@metalight.ai

• Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
• 500,000-1 million people are estimated to be living with FSGS in the territories^[1]
• Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481^[2] million, plus royalties
  • US$10 million (~AU$14.1 million²) upfront payment
  • Up to US$330 million (~AU$467 million²) in potential milestone payments
  • Tiered royalties on net sales
• Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma (announced October 2023)^[3], Taiba Rare (announced May 2024)^[4], Fuso Pharmaceutical Industries (announced 7 January 2025)^[5], and Amicus Therapeutics (announced 1 May 2025, now BioMarin)^[6]; with over AU$65 million having been received prior to the Everest transaction
• Collectively across the 5 transactions, Dimerix may be eligible to receive up to ~AU$1.9 billion^[7] in aggregate total upfront and potential milestone payments, plus additional royalties on net sales
• DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and serious kidney disease with no approved therapies across these regions
• The ACTION3 Phase 3 clinical trial is fully recruited, with patients enrolled across 21 countries, including Chinese mainland, Hong Kong SAR, Taiwan region, Thailand and Malaysia
• Everest will leverage its specialty kidney disease expertise and commercial platform to register and commercialise DMX-200, offering greater patient access to the growing Asian markets
• Dimerix retains all rights to DMX-200 in all other unlicensed territories

MELBOURNE, Australia, June 16, 2026 /PRNewswire/ — Dimerix Limited (ASX: DXB, “Dimerix”) today announced that it has entered into an exclusive license agreement with Everest Medicines for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 for all indications including FSGS, in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). Dimerix retains all rights to commercialise DMX-200 in all territories other than those already exclusively licensed.

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disease. The ACTION3 Phase 3 clinical trial adult cohort is fully recruited, with 333 patients, including patients in the licensed territories.

In early 2024, Dimerix reported positive interim results from the ACTION3 trial in FSGS, showing DMX-200 was performing better than placebo in reducing proteinuria at that time.^[8] There have been no safety concerns to date following 8 reviews by the independent data monitoring committee, the most recent in June 2026. In April 2026, an external statistical blinded review of ACTION3 data achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial’s conclusion.^[9]

“We are delighted to establish this partnership with Everest Medicines, a company with strong rare renal disease expertise and a proven track record in commercialising in Greater China, South Korea and certain Southeast Asian countries. Importantly, this collaboration significantly expands the potential reach of DMX-200 into a large and underserved patient population. Everest is well positioned to maximise the opportunity in the licensed regions, while allowing Dimerix to retain focus on progressing our global registrational program, delivering value for shareholders and providing real hope for patients with FSGS across the globe in need of treatment options.”

Dr Nina Webster, CEO & Managing Director, Dimerix

“This collaboration with Dimerix marks an important step in advancing our strategic focus in kidney disease and further strengthening our innovative renal portfolio. Patients with FSGS in China have long faced significant unmet medical needs due to the lack of targeted treatment options. The positive interim results from the global pivotal Phase 3 study of DMX-200 underscore its potential to offer a meaningful new therapy for these patients.

Leveraging our proven expertise in clinical development and commercialisation, we are committed to accelerating access to DMX-200 in China and beyond and exploring other glomerulopathies. We look forward to working closely with Dimerix to bring this innovative therapy to more patients in need.”

Yifang Wu, Chairman of the Board, Everest Medicines

Dimerix will continue to fund and execute the ACTION3 study, and Everest will be responsible for supporting submission and maintenance of the regulatory dossier in the licensed territories, as well as all costs of commercialisation activities. Everest and Dimerix will form a Joint Steering Committee to align the development and commercialisation of DMX-200 in FSGS in the licensed territories. The agreement otherwise contains terms common for an arrangement of this kind.

In exchange for these rights, Dimerix is to receive a US$10 million (~AU$14.1 million^[2]) upfront payment within 45 business days of execution. In total, Dimerix is eligible to receive potential success-based development and regulatory milestones payments of up to US$30 million (~AU$42.4 million^[2]) and commercial milestone payments of up to US$300 million (~AU$424.4 million^[2]), with tiered royalties on DMX-200 net sales of between 10-15% in Greater China, South Korea, and certain Southeast Asian countries. Note that milestone payments are not broken down further, as that can negatively influence negotiations of contracts in other territories currently under discussion, and thus remains commercial in confidence. All contracted financial terms are denominated in U.S. dollars.

Authorised for lodgement with ASX by the Board of Dimerix.

—END— 

About ACTION3 Phase 3 Study
The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

About DMX-200
DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan^[10].

About FSGS
FSGS is a serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. The pathogenesis of FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In China, 500,000 to 1 million people^[1] are estimated to be living with FSGS, including both adults and children. Management relies on non-specific immunosuppressive and supportive therapies in most countries around the world. In patients with progressive or treatment-resistant FSGS, the time from diagnosis to end-stage kidney disease can be as short as five years. Even among those with FSGS who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,^[11] underscoring the urgent need for new disease-modifying treatments.

About Dimerix Limited
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company’s website at www.dimerix.com and follow on X and LinkedIn.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercialising innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialisation platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website at www.everestmedicines.com.

Dimerix Forward Looking Statement
This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

References

SHANGHAI, June 16, 2026 /PRNewswire/ — ZTO Express (Cayman) Inc. (NYSE: ZTO and HKEX: 2057), a leading and fast-growing express delivery company in China (“ZTO” or the “Company”), today announced that each of the following proposed resolutions submitted for shareholder approval has been adopted as an ordinary resolution at its annual general meeting of shareholders held in Hong Kong today:  

About ZTO Express (Cayman) Inc.

ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) (“ZTO” or the “Company”) is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit https://zto.investorroom.com.

Safe Harbor Statement

This announcement contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and other similar expressions. ZTO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its interim and annual reports to shareholders, in announcements, circulars or other publications made on the website of the HKEX, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including but not limited to statements about ZTO’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: risks relating to the development of the e-commerce and express delivery industries in China; its significant reliance on certain third-party e-commerce platforms; risks associated with its network partners and their employees and personnel; intense competition which could adversely affect the Company’s results of operations and market share; any service disruption of the Company’s sorting hubs or the outlets operated by its network partners or its technology system; ZTO’s ability to build its brand and withstand negative publicity, or other favorable government policies. Further information regarding these and other risks is included in ZTO’s filings with the SEC and the HKEX. All information provided in this announcement is as of the date of this announcement, and ZTO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

ZTO Express (Cayman) Inc.

Investor Relations
E-mail: ir@zto.com
Phone: +86 21 5980 4508